NASDAQ · TDACW

Translational Development Acquisition Corp.

$2.02 +$0.25 (+14.12%) 1D Market open
Session Pulse Pre-market 1 mentions on Mon 1 SEC filing since Mon close 8-K its sector ranked 4/11 this week Full pulse →

Key Metrics

Market cap
P/E · TTM
Revenue · TTM
−$150.28K
Net income
EPS · TTM
Dividend yield
Free cash flow
Beta · 1Y 0.79
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 27
    A material event was filed (Form 8-K).

    8-K - Translational Development Acquisition Corp. (0001926599) (Filer)

    RECEIPT: SEC FORM 8-K, TIMESTAMPED
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 9
    The stock moved +25.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 9
  • May 27
    The stock moved +920.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 27
  • Apr 24
    From its Jan 30 high, the share price fell 68%.

    Peak close $0.31 on Jan 30; trough close $0.10 on Apr 24. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -68%

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap
Enterprise value
Shares outstanding
52-wk range$0.06 – $2.80
Avg volume · 20D297.7K
Net cash
Book value / share
IndustryBlank Checks
ExchangeNASDAQ
About Translational Development Acquisition Corp.
IPO dateFeb 13, 2025
Employees

Translational Development Acquisition Corp is a newly organized blank check company.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC 2.4% · —

Financial Health

Current ratio0.09
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital−$785.77K

Cash Flow · TTM

Operating CF
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

0 / 9
Weak fundamentals · 0 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings